TOP STORIES
We’ve likely said all you need to know about the Pfizer-Allergan merger. But here’s a wrap of most notable analysis from across the web.
- Ian Read to American politicians: This deal is good for the United States. – The New York Times
- First the merger, then the split: One business focuses on new and high-growth products (Ibrance and Botox). The other takes the old businesses like Celebrex and Teflaro. – Wall Street Journal
- “Unlike previous M&A deals, this one won’t create that much in synergies…” – Forbes
- A universal political pounding. – The Washington Post & Vox
- This deal can’t be blocked by U.S. regulators. – USA Today
- “Even more difficult to quantify is the effect on productivity…” What becomes of R&D? – FierceBiotech
- Could the deal push up drug prices and spur more such deals? – Associated Press
- “Here’s the problem: Instead of a culture of discovery and innovation, the accountants are in charge and you better do whatever they say.” – STAT
- Can Pfizer re-invent itself now? – CNBC
- Pfizer’s Huge Deal Could Work, but With Adverse Effects – New York Times
- How the Pfizer-Allergan deal will impact the Bay area (and maybe some of Pfizer’s investments) – San Francisco Business Times
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
LIFE SCIENCES
Novartis’ heart failure drug Entresto has been improved in Europe. – MarketWatch
M3 Biotechnology is raising capital for a Phase 1 Alzheimer’s trial, apply for fast-track status with the FDA, and build its pipeline. – Puget Sound Business Journal
AstraZeneca sold its Crohn’s disease drug Entocort to Perrigo for $380 million – part of the broader strategy to sell non-core products to fill its short-term revenue gap. – Economic Times
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Bristol-Myers Squibb wins FDA approval for its immunotherapy treatment Opdivo for patients with advanced renal cell carcinoma. – Pharma Times
Electrophysiology recording company BioSig Technologies has started raising a fresh round of capital ($1 million so far). – Minneapolis-St. Paul Business Journal
Swiss biopharma ObsEva said $60 million from the likes of NEA, Novo Ventures and Orbimed, to focus on “serious conditions compromising pregnancy from conception to birth.” – PE Hub
PAYERS/PROVIDERS
Thanks, Obama! “In 2014, tech companies targeting the insurance space took less than $700M in funding. In just the first nine months of 2015, insurance tech startups have attracted more than three times as much funding…” – CB Insights
The John P. McGovern Foundation donated $75 million to the University of Texas Health Science Center at Houston and its medical school. In other news, the medical school will be renamed the John P. and Kathrine G. McGovern Medical School. – Austin Business Journal
TECH
Certain FitBits will now be able to tell if you’re on an elliptical, biking outdoors, running, or walking. – MobiHealthNews
A LITTLE EXTRA
The federal government may have lost a critical bit of footage from the JFK assassination – and is not being sued for $10 million over it. – Gizmodo